<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04275557</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-20105</org_study_id>
    <secondary_id>1R37CA229810-01A1</secondary_id>
    <nct_id>NCT04275557</nct_id>
  </id_info>
  <brief_title>Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas</brief_title>
  <official_title>Using Radiogenomics to Noninvasively Predict the Malignant Potential of Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas and Uncover Hidden Biology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Florida Pancreas Collaborative wants to partner with individuals who are known to have,&#xD;
      or are suspected to have a pancreatic lesion, tumor, cyst, mass, cancer, or pancreatitis and&#xD;
      are undergoing diagnosis and treatment at a participating institution. The goals of this&#xD;
      project are to build a large database of information obtained from blood, tissue, medical&#xD;
      images, surveys and information from routine care to develop noninvasive diagnostic&#xD;
      approaches that could be used as decision-making tools to effectively personalize clinical&#xD;
      care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2020</start_date>
  <completion_date type="Anticipated">February 2027</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive value of CT Radiomic features vs conventional radiologic features</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Preoperative CT images will be evaluated for a retrospective cohort of at least 254 pathologically-confirmed IPMN cases (approximately 190 malignant characterized by high-grade dysplasia or invasion and approximately 64 benign characterized by low- or moderate-grade dysplasia). 3D-radiomic features will be extracted with the new Quantitative Imaging Decision Support (QIDS)â„¢ platform (Healthmyne, Inc.) and associations will be evaluated with pathology.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of Clinical Decision Making Models for Predicting IPMN Pathology</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Investigators will develop the first prototype preoperative 'omics'-based nomograms to predict IPMN pathology by integrating radiomic features, the MGC, and other covariates. Emphasis will be placed on developing nomograms for individuals whose IPMNs appear to have 'worrisome' radiologic features which are very challenging to manage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiogenomic Analyses</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Investigators will conduct the first radiogenomic analyses of IPMNs by evaluating the relationship between radiomic features and tissue and circulating levels of candidate biomarkers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Overall survival is defined as time from surgery to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Progression free survival is defined as time from surgery to either pancreatic cancer recurrence or death.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1174</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Pancreatic Cyst</condition>
  <arm_group>
    <arm_group_label>Retrospective Cohort</arm_group_label>
    <description>Retrospective chart review of pathologically-confirmed Intraductal Papillary Mucinous Neoplasm (IPMN) cases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective Cohort</arm_group_label>
    <description>Blood, tumor tissue samples and data will be collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Sample collection</intervention_name>
    <description>Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date), 4-6 weeks post-surgery, if applicable, and at the time of follow-up (approximately 1 year and approximately 2 years after baseline).</description>
    <arm_group_label>Prospective Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tissue sample collection</intervention_name>
    <description>At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue, muscle, fat, tissue from site of metastasis, and cyst fluid (if applicable) will be collected.</description>
    <arm_group_label>Prospective Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Participants will be asked to complete questionnaires at baseline and at 1 year and 2 year follow-ups.</description>
    <arm_group_label>Prospective Cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood, Plasma, Serum, Tumor tissue from biopsy or surgery, Muscle and fat tissue from&#xD;
      surgery, cyst fluid, cytology supernatant, peripheral blood monocular cells (PMBCs)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of the GI clinic, surgery, or endoscopy at Moffitt Cancer Center, University of&#xD;
        Florida - Gainesville, or the University of Miami - Jackson Memorial Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals who present to the GI clinic, surgery, or endoscopy at Moffitt, Florida&#xD;
             Research Institute (FRI), or UM with a clinical suspicion for (or diagnosis of) a&#xD;
             pancreatic lesion, cyst, mass, cancer, or pancreatitis based on symptoms, imaging, or&#xD;
             blood-work and has not had any treatment involving their pancreas.&#xD;
&#xD;
          -  Able to understand and voluntarily sign the informed consent.&#xD;
&#xD;
          -  Willing to complete study questionnaire(s) and donate medical images and biological&#xD;
             specimens (including blood, cystic fluid, and tissue) obtained at the time of standard&#xD;
             of care procedures (biopsy, surgery, and venipuncture) after signing the informed&#xD;
             consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No suspicion or diagnosis of a pancreatic lesion, cyst, mass, cancer, or pancreatitis.&#xD;
&#xD;
          -  Has a diagnosis of a pancreatic lesion, cyst, mass, cancer, or pancreatitis and has&#xD;
             already undergone treatment involving the pancreas (which may involve surgery, chemo-&#xD;
             or immuno-therapy, and/or radiation).&#xD;
&#xD;
          -  Unable to provide informed consent.&#xD;
&#xD;
          -  Unwilling to complete study questionnaire(s) and/or donate biological specimens or&#xD;
             images.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Permuth, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saira Bahl, MSc</last_name>
    <phone>813-745-4752</phone>
    <email>Saira.Bahl@moffitt.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Toni Basinski</last_name>
    <phone>813-745-6360</phone>
    <email>Toni.Basinski@moffitt.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Florida Research Institute (FRI)</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arun Khazanchi, MD</last_name>
      <phone>941-727-7772</phone>
      <email>arun.khazanchi@fdhs.com</email>
    </contact>
    <investigator>
      <last_name>Arun Khazanchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center &amp; Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nipun B Merchant, MD, FACS</last_name>
      <phone>305-243-7160</phone>
      <email>nmerchant@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Nipun B Merchant, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saira Bahl, MSc</last_name>
      <phone>813-745-4752</phone>
      <email>Saira.Bahl@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer B Permuth, PhD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Jeong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic Lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Pancreatic Cyst</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

